Redx Pharma Plc said it was “pleased with progress” as it posted its first half-year figures since listing on AIM.
Seneca EIS portfolio company Redx which raised £15m in March, increased its interim loss from £2m to £3.3m on revenue of £5.5m (£5.2m in 2014.)
Redx is working in three main areas – oncology, immunology and anti-infectives.
Chief executive Dr Neil Murray said: “There are no great surprises in these results. We are pleased with the progress we have made since the IPO and how the pipline is developing. I remain very optimistic about the opportunities available to us and Redx’s admission to AIM and share placing at the end of March will help to support our ambitious plans for our ongoing development.”
See the article in full at TheBusinessDesk.com.